This company listing is no longer active
I4P Stock Overview
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Intercept Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.52 |
| 52 Week High | US$19.97 |
| 52 Week Low | US$8.16 |
| Beta | 0.88 |
| 1 Month Change | 0.46% |
| 3 Month Change | 90.52% |
| 1 Year Change | 14.92% |
| 3 Year Change | -45.23% |
| 5 Year Change | -79.17% |
| Change since IPO | 17.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| I4P | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -11.3% | 3.0% |
| 1Y | 14.9% | -15.0% | 19.3% |
Return vs Industry: I4P exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: I4P exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| I4P volatility | |
|---|---|
| I4P Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I4P's share price has been volatile over the past 3 months.
Volatility Over Time: I4P's weekly volatility has increased from 15% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 341 | Jerry Durso | www.interceptpharma.com |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
Intercept Pharmaceuticals, Inc. Fundamentals Summary
| I4P fundamental statistics | |
|---|---|
| Market cap | €742.08m |
| Earnings (TTM) | -€53.66m |
| Revenue (TTM) | €296.65m |
2.5x
P/S Ratio-13.8x
P/E RatioIs I4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I4P income statement (TTM) | |
|---|---|
| Revenue | US$317.68m |
| Cost of Revenue | US$632.00k |
| Gross Profit | US$317.05m |
| Other Expenses | US$374.52m |
| Earnings | -US$57.47m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 99.80% |
| Net Profit Margin | -18.09% |
| Debt/Equity Ratio | 311.6% |
How did I4P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/09 02:42 |
| End of Day Share Price | 2023/11/07 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intercept Pharmaceuticals, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Geoffrey Meacham | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |